CHA Biomedical Group announced on Wednesday it will participate in the world's largest bio exhibition, 2023 BIO International Convention, to be be held in Boston, from June 5 to 9.

Affiliates of CHA Biomedical Group -- Matica Biotechnology, CHA Biotech, and CHA Vaccine Research Institute -- will explore opportunities for global business expansion at BIO 2023.

Matica Biotechnology, the U.S. offshoot of CHA Biotech, will introduce its competitiveness in CDMO (contract development and manufacturing) of third-generation cell and gene therapies. It plans to set up an exhibition booth and meet with more than 30 clients and potential clients to promote its technology and win orders actively. A 3D virtual tour of the company's CDMO facility in Texas will also be available for clients.

In May 2022, Matica Biotechnology became the first Korean company to open a cell and gene therapy CDMO facility in College Station, Texas. The company is pushing to build a second plant capable of producing commercialization-stage drugs. The company is expanding its business scope to include the development and production of viral vectors, a key raw material for cell and gene therapies, as well as the production of various cell therapies.

CHA Biotech will actively communicate the status of investigational cell therapy products to discuss technology transfer and joint development. In particular, the company is considering the introduction of a chimeric antigen receptor (CAR) to maximize the therapeutic properties and effectiveness of NK therapeutics.

CHA Biotech is developing a pipeline of immune and stem cell therapies centered on diseases with high clinical needs using disease-specific customized cell lines. 

Among them, the company has completed a phase 1 trial of CBT101, an anti-cancer immune cell therapy being developed based on NK cells, and is preparing for global phase 2 trials.

CHA Vaccine Research Institute was named “presentation company” at BIO 2023. Presentation companies can communicate with many global companies through podium presentations and have technology transfer opportunities. 

Yeom Jeong-seon, CEO of CHA Vaccine Research Institute, will introduce the company's proprietary immune enhancer platform and clinical pipeline in a presentation on June 5 at 14:25, local time.

In a business partnering meeting, the vaccine institute will discuss technology transfer and joint development of shingles vaccines and immune enhancers, including a vaccine for the treatment of chronic hepatitis B. The institute will complete a phase 2b trial later this year.